Quality of life from cytoreductive surgery in advanced Ovarian cancer: investigating association with disease burden and surgical complexity in the international, prospective, SOCQER2 cohort study

Objective: \ud To investigate quality of life (QoL) and association with surgical complexity and disease burden after surgical resection for advanced ovarian cancer in centres with variation in surgical approach\ud \ud Design: \ud Prospective multicentre observational study\ud \ud Setting: \ud United Kingdom, Kolkata, India, and Melbourne, Australia gynaecological cancer surgery centres.\ud \ud Participants: \ud Patients undergoing surgical resection for late stage ovarian cancer.\ud \ud Exposure Low, intermediate or high Surgical Complexity Score (SCS) surgery\ud \ud Main outcomes and measures: \ud Primary: EORTC-QLQ-C30 Global score change. Secondary: EORTC OV28, progression free survival.\ud \ud Results: \ud Patients’ pre-operative disease burden and SCS varied between centres, confirming differences in surgical ethos. QoL response rates were 90% up to 18 months. Mean change from the pre-surgical baseline in the EORTC QLQ-C30 was 3.4 (SD 1.8, n=88) in the low, 4.0 (SD 2.1, n=55) in the intermediate and 4.3 (SD 2.1, n=52) in the high SCS group after 6 weeks (p=0.048) and 4.3 (SD 2.1, n=51), 5.1 (SD 2.2, n=41) and 5.1 (SD 2.2, n=35) respectively after 12 months (p=0.133). In a repeated measures model, there were no clinically or statistically meaningful differences in EORTC QLQ-C30 global scores between the three SCS groups, p= 0.840 but there was a small statistically significant improvement in all groups over time (p